{"id":742156,"date":"2012-12-03T06:30:00","date_gmt":"2012-12-03T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/"},"modified":"2023-03-22T00:04:20","modified_gmt":"2023-03-22T04:04:20","slug":"merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/","title":{"rendered":"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer&#8217;s Disease"},"content":{"rendered":"<p class=\"bwalignc\">       Phased study to evaluate safety and efficacy of MK-8931 in        patients with mild-to-moderate Alzheimer&#8217;s disease     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced it has started a Phase II\/III clinical trial designed to<br \/>\n      evaluate the safety and efficacy of MK-8931 versus placebo in patients<br \/>\n      with mild-to-moderate Alzheimer&#8217;s disease. MK-8931 is Merck&#8217;s novel<br \/>\n      investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme<br \/>\n      (BACE) inhibitor, and is the first with this mechanism to advance to<br \/>\n      this stage of clinical research. The global, multi-center study, called<br \/>\n      EPOCH, is designed to initially evaluate the safety of MK-8931 in a<br \/>\n      cohort of 200 patients prior to advancing into a larger Phase III study.\n    <\/p>\n<p>\n      &#8220;Merck is committed to advancing the understanding and treatment of<br \/>\n      Alzheimer&#8217;s disease,&#8221; said Darryle D. Schoepp, Ph.D., senior vice<br \/>\n      president and head of Neuroscience and Ophthalmology, Merck Research<br \/>\n      Laboratories. &#8220;As the global health and financial burden of Alzheimer&#8217;s<br \/>\n      disease grows, innovative research is critically needed, and we need to<br \/>\n      accelerate this research wherever possible. This new study is an<br \/>\n      important step in our overall strategy to understand the potential of<br \/>\n      the BACE inhibitor mechanism and MK-8931, our lead compound, in multiple<br \/>\n      stages of Alzheimer&#8217;s disease.&#8221;\n    <\/p>\n<p>\n      <b>About the EPOCH study<\/b>\n    <\/p>\n<p>\n      EPOCH is a 78-week, randomized, placebo-controlled, parallel-group,<br \/>\n      double-blind Phase II\/III clinical trial to evaluate the efficacy and<br \/>\n      safety of one of three oral doses of MK-8931 (12, 40 or 60 mg)<br \/>\n      administered daily versus placebo. The study is anticipated to<br \/>\n      eventually enroll up to 1,700 patients in the main Phase III cohort. The<br \/>\n      primary efficacy outcomes of the study are the change from baseline in<br \/>\n      Alzheimer&#8217;s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score<br \/>\n      and the change from baseline in the Alzheimer&#8217;s Disease Cooperative<br \/>\n      Study \u2013 Activities of Daily Living (ADCS-ADL) score.\n    <\/p>\n<p>\n      For more information about the EPOCH study, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ADstudyinfo.com&amp;esheet=50494844&amp;lan=en-US&amp;anchor=www.ADstudyinfo.com&amp;index=1&amp;md5=4967d29b77f72b6a7181eabc7cd42515\">www.ADstudyinfo.com<\/a><br \/>\n      or call 1-855-55-EPOCH (37624).\n    <\/p>\n<p>\n      <b>About BACE Inhibition and MK-8931<\/b>\n    <\/p>\n<p>\n      The amyloid hypothesis asserts that the formation of amyloid peptides<br \/>\n      that lead to amyloid plaque deposits in the brain is the underlying<br \/>\n      cause of Alzheimer&#8217;s disease. BACE is believed to be a key enzyme in the<br \/>\n      production of amyloid \u03b2 peptide. Evidence suggests that inhibiting BACE<br \/>\n      decreases the production of amyloid \u03b2 peptide and may therefore reduce<br \/>\n      amyloid plaque formation and modify disease progression.\n    <\/p>\n<p>\n      Earlier this year, Merck researchers presented findings of a multiple<br \/>\n      dose Phase I study which demonstrated that MK-8931 can reduce cerebral<br \/>\n      spinal fluid (CSF) \u03b2-amyloid by greater than 90 percent in healthy<br \/>\n      volunteers, without dose limiting side effects.\n    <\/p>\n<p>\n      Merck is advancing several innovative mechanisms in Alzheimer&#8217;s disease,<br \/>\n      including candidates designed to modify disease progression and improve<br \/>\n      symptom control. Merck&#8217;s major effort in disease modification is our<br \/>\n      lead BACE inhibitor, MK-8931, and Merck is continuing to develop other<br \/>\n      BACE inhibitor candidates.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50494844&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=80189cd3a9f30f2d3fdaedc89f427661\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50494844&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=d1fc331b69ce11d8039d0783b85856a7\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Media:<br \/>Merck<br \/>Caroline Lappetito, 908-423-3046<br \/>or<br \/>Investors:<br \/>Merck<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phased study to evaluate safety and efficacy of MK-8931 in patients with mild-to-moderate Alzheimer&#8217;s disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II\/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer&#8217;s disease. MK-8931 is Merck&#8217;s novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study. &#8220;Merck is committed to advancing the understanding and treatment of Alzheimer&#8217;s disease,&#8221; said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. &#8220;As the global health and financial burden<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742156","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer&#039;s Disease - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer&#039;s Disease - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Phased study to evaluate safety and efficacy of MK-8931 in patients with mild-to-moderate Alzheimer&#039;s disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II\/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer&#039;s disease. MK-8931 is Merck&#039;s novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study. &quot;Merck is committed to advancing the understanding and treatment of Alzheimer&#039;s disease,&quot; said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. &quot;As the global health and financial burden\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/\",\"name\":\"Merck Initiates Phase II\\\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-12-03T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Initiates Phase II\\\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease - Merck.com","og_description":"Phased study to evaluate safety and efficacy of MK-8931 in patients with mild-to-moderate Alzheimer's disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II\/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease. MK-8931 is Merck's novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study. \"Merck is committed to advancing the understanding and treatment of Alzheimer's disease,\" said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. \"As the global health and financial burden","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/","name":"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-12-03T06:30:00+00:00","dateModified":"2023-03-22T04:04:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121203005589r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-ii-iii-study-of-investigational-bace-inhibitor-mk-8931-for-treatment-of-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Initiates Phase II\/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"819d66d8-0042-4f7b-bf2a-290da19053b0","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Initiates-Phase-IIIII-Study-of-Investigational-BACE-Inhibitor-MK-8931-for-Treatment-of-Alzheimers-Disease-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742156\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742156"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}